Home > Browse Issues > Vol.40 No.3
Demands， Challenges and Progresses of Prophylactic Hepatitis C Virus Vaccine Development
Yan Yu, Wang Xuesong, Huang Zhong*, Zhong Jin*
Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
Abstract: Hepatitis C virus (HCV) infects about 70 million people in the world， imposing a major threat to public health. The recently developed direct antiviral drugs overcame the shortcomings of the traditional interferon-based hepatitis C therapy and improved the virological response. However， challenges remain including high therapeutic costs and drug-resistant viral mutations. HCV infections are often persistent and subclinical， and the frequencies of new and re-occurring infection are high in the high-risk groups. Therefore， development of a prophylactic vaccine is imperative to control of HCV transmission. However， no HCV vaccine is available at the present due to the high viral genome variability and other factors. This article summarizes the demand， challenges， recent progress and future direction in prophylactic HCV vaccine development.
CN
EN